SAN DIEGO, Nov. 11, 2011 /PRNewswire/ -- Orexigen ® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at the Lazard Capital Markets Healthcare Conference in New York. The presentation is scheduled for Wednesday, November 16th at 8:00 a.m. EST ( 5:00 a.m. PST).
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials, and the Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.
SOURCE Orexigen Therapeutics, Inc.